Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tocilizumab.

Literature DB >> 20065633

Tocilizumab.

Abstract

Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2009 PMID： 20065633 PMCID： PMC2759492 DOI： 10.4161/mabs.1.5.9497

Source DB: PubMed Journal: MAbs ISSN： 1942-0862 Impact factor: 5.857

19 in total

1. Tocilizumab.

Authors: Clemens Scheinecker; Josef Smolen; Uma Yasothan; Jeffrey Stoll; Peter Kirkpatrick
Journal: Nat Rev Drug Discov Date: 2009-04 Impact factor: 84.694

2. Actemra poised to launch IL-6 inhibitors.

Authors: Lisa Melton; Amy Coombs
Journal: Nat Biotechnol Date: 2008-09 Impact factor: 54.908

Review 3. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Authors: M Feldmann; R N Maini
Journal: Annu Rev Immunol Date: 2001 Impact factor: 28.527

4. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis.

Authors: A S de Hooge; F A van De Loo; O J Arntz; W B van Den Berg
Journal: Am J Pathol Date: 2000-12 Impact factor: 4.307

5. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Authors: N Nishimoto; M Sasai; Y Shima; M Nakagawa; T Matsumoto; T Shirai; T Kishimoto; K Yoshizaki
Journal: Blood Date: 2000-01-01 Impact factor: 22.113

6. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Authors: Shumpei Yokota; Tomoyuki Imagawa; Masaaki Mori; Takako Miyamae; Yukoh Aihara; Shuji Takei; Naomi Iwata; Hiroaki Umebayashi; Takuji Murata; Mari Miyoshi; Minako Tomiita; Norihiro Nishimoto; Tadamitsu Kishimoto
Journal: Lancet Date: 2008-03-22 Impact factor: 79.321

7. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Authors: Norihiro Nishimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Junichi Azuma; Tadamitsu Kishimoto
Journal: Mod Rheumatol Date: 2008-11-01 Impact factor: 3.023

8. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors: N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal: Ann Rheum Dis Date: 2008-11-19 Impact factor: 19.103

9. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.

Authors: G Jones; A Sebba; J Gu; M B Lowenstein; A Calvo; J J Gomez-Reino; D A Siri; M Tomsic; E Alecock; T Woodworth; M C Genovese
Journal: Ann Rheum Dis Date: 2010-01 Impact factor: 19.103

10. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors: P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal: Ann Rheum Dis Date: 2008-07-14 Impact factor: 19.103

28 in total

1. Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.

Authors: Shalini Chaturvedi; Derick Siegel; Carrie L Wagner; Jaehong Park; Helgi van de Velde; Jessica Vermeulen; Man-Cheong Fung; Manjula Reddy; Brett Hall; Kate Sasser
Journal: Br J Clin Pharmacol Date: 2015-06-04 Impact factor: 4.335

Review 2. Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors: Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal: Expert Rev Neurother Date: 2017-01-29 Impact factor: 4.618

Review 3. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.

Authors: Zohreh Sadat Badieyan; Sayed Shahabuddin Hoseini
Journal: Arch Immunol Ther Exp (Warsz) Date: 2018-02-09 Impact factor: 4.291

4. Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms.

Authors: H Engler; P Brendt; J Wischermann; A Wegner; R Röhling; T Schoemberg; U Meyer; R Gold; J Peters; S Benson; M Schedlowski
Journal: Mol Psychiatry Date: 2017-01-31 Impact factor: 15.992